Stayble Therapeutics' clinical phase IIb study with STA363 takes no break in the summer heat. Approximately 90 per cent of the patients have now completed their 12-month follow-up, which shows that the company has good opportunities to present top-line data during the fourth quarter of this year. The company's CEO Andreas Gerward tells us more in an interview.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/07/staybles-phase-iib-study-nears-the-finishing-line/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/stayble-therapeutics/r/biostock-stayble-s-phase-iib-study-nears-the-finishing-line,c3808947

(c) 2023 Cision. All rights reserved., source Press Releases - English